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Abstract
To study the protective effects of maternal thyroxine (T4) and
3,5,3'-triiodothyronine (T3) in congenital hypothyroidism, we
gave pregnant rats methimazole (MMI), an antithyroid drug
that crosses the placenta, and infused them with three different
doses of T4 or T3. The concentrations of both T4 and T3 were
determined in maternal and fetal plasma and tissues (obtained
near term) by specific RIAs. Several thyroid hormone-depen-
dent biological end-points were also measured. MMI treat-
ment resulted in marked fetal T4 and T3 deficiency. Infusion of
T4 into the mothers increased both these pools in a dose-de-
pendent fashion. There was a preferential increase of T3 in the
fetal brain. Thus, with a T4 dose maintaining maternal euthy-
roidism, fetal brain T3 reached normal values, although fetal
plasma T4 was 40% of normal and plasma TSH was high. The
infusion of T3 into the mothers increased the total fetal ex-
trathyroidal T3 pool in a dose-dependent fashion. The fetal T4
pools were not increased, however, and this deprived the fetal
brain (and possibly the pituitary) of local generation ofT3 from
T4. As a consequence, fetal brain T3 deficiency was not miti-
gated even when dams were infused with a toxic dose of T3.
The results show that (a) there is a preferential protection of
the brain of the hypothyroid fetus from T3 deficiency; (b) ma-
ternal T4, but not T3, plays a crucial role in this protection, and
(c) any condition which lowers maternal T4 (including treat-
ment with T3) is potentially harmful for the brain of a hypothy-
roid fetus. Recent confirmation of transplacental passage of T4
in women at term suggests that present results are relevant for
human fetuses with impairment of thyroid function. Finding
signs of hypothyroidism at birth does not necessarily mean
that the brain was unprotected in utero, provided maternal T4
is normal. It is crucial to realize that maintainance of maternal
"euthyroidism" is not sufficient, as despite hypothyroxinemia,
the mothers may be clinically euthyroid if their T3 levels are
normal. (J. Clin. Invest. 1990. 86:889-899.) Key words: cre-
tinism * placenta - 5' deiodinase * TSH - hypothyroxinemia
Introduction
For years the mammalian placenta has been considered vir-
tually impermeable to the thyroid hormones, L-thyroxine (T4)
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and 3,5,3'-triiodo-L-thyronine (T3) (1, 2). Thus, thyroid hor-
mones would not be required for normal embryonic develop-
ment before onset of fetal thyroid function (3, 4). It has, how-
ever, been shown that rat and human embryonic tissues con-
tain T4 and T3 before onset of fetal thyroid function, and that
both are of maternal origin (5-8). The nuclear receptor for T3
is also found in human and rat brain early in pregnancy (7, 9).
The adverse effects of maternal hypothyroxinemia on the cen-
tral nervous system (CNS) might be related to the thyroid
hormone deficiency ofthe developing embryo (5, 8, 10-12). In
neurologic endemic cretinism the degree ofthe developmental
disorders has been correlated to with that of maternal hypo-
thyroxinemia (1 3).
Even when transfer of maternal thyroid hormones early in
pregnancy is accepted (14), it is believed that maternal transfer
would not be necessary once the fetal thyroid is active; placen-
tal inner ring deiodinations would prevent the iodothyronines
from reaching the fetus (2, 15). The fetal pituitary-thyroid axis
functions with a great degree of autonomy: thyroid failure is
accompanied by low T4 and elevated serum TSH levels. This,
however, does not necessarily mean total independence from
maternal thyroid status. Transfer of maternal thyroid hor-
mones might still continue, and mitigate the effects of thyroid
hormone deficiency until birth.
We have shown in rats that both T4 and T3 continue to be
transferred from the mother to the fetus near term, when the
fetal thyroid is impaired (16, 17). The infusion of T4 to the
mother (16) mitigated both T4 and T3 deficiency of the
methyl-mercapto-imidazole-2-thiol (MMI)-treated fetus. The
brain actually attained normal concentrations ofT3, at present
considered as the intracellularly active iodothyronine (18). In
contrast, the infusion ofT3 to the mother did not mitigate fetal
cerebral T3 deficiency, although it increased the concentra-
tions of T3 in other fetal tissues ( 17).
These previous studies did not clarify several points of in-
terest: (a) the range of maternal doses of T4 that would ensure
normal T3 levels in the fetal brain; (b) whether, or not, a su-
praphysiological maternal supply of T4 would result in exces-
sive concentrations of T3 in the fetal brain, and (c) whether or
not, normalization of fetal brain T3 would eventually be at-
tained with higher doses of maternal T3 than previously used.
Such information may well be relevant to babies with congeni-
tal hypothyroidism. It has been recently shown by Vulsma et
al. ( 19) that T4 is transferred from the mother to the hypothy-
roid baby up to birth: T4 levels in cord-blood from babies with
total organification defect ranged from 2.7 to 5.4 ,g/dl,
namely 25 to 50% of normal values, then decreasing with a
1. Abbreviations used in this paper: a-GPD, a-glycerophosphate dehy-
drogenase; BAT, brown adipose tissue; Cx, cerebral cortex; 5' n-I, type
II 5'-iodothyronine deiodinase; MMI, methimazole l-methyl-mer-
capto-imidazole-2-thiol; PTU, 6-N-propyl-2-thiouracil
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half-life of disappearance of 3.6 d. Thus, in contrast with pre-
vious widespread opinion, maternal thyroid hormones might
protect the human hypothyroid fetus, and especially its brain,
at least up to birth.
The present paper reports results obtained in fetuses from
rats treated with MMI, and infused with T4 or T3, at three
different dose levels of each.
Methods
Experimental design. Female rats of a Wistar strain were used. They
were mated with normal males, the day ofappearance ofa vaginal plug
being considered as day 0 ofgestation (8). They were divided into eight
different groups (Table I), comprising three dams each: seven of the
eight groups were given 0.02% MMI as drinking water, starting on the
morning ofthe 14th day ofgestation (MMI dams). The eighth group (C
dams) did not receive MMI. At 15 d of gestation, all the dams were
implanted with osmotic minipumps delivering at a constant rate either
infusion solvent (dams of the C group and of one MMI group), T4
(three MMI + T4 groups) or T3 (three MMI + T3 groups). The doses of
T4 and T3 are shown in Table I. The dams were killed at 21 d of
gestation, and perfused as previously described in detail (8), except that
6-N-propyl-2-thiouracil (PTU) was not added to the perfusion medium
to avoid possible interferences with the measurements of outer-ring
iodothyronine deiodinase activities. We used a total of 24 dams and
their 223 fetuses.
Continuous infusion of T4 and T3. We used 2-ml Alzet osmotic
minipumps (Alza Corp., Palo Alto, CA), implanted under the dorsal
skin (16). The pumps delivered 5 gl/h for 14 d. The minipumps im-
planted into the C and MMI dams contained only the infusion solvent,
namely phosphosaline buffer, pH = 7.4, containing 5% serum from
thyroidectomized rats. T4 or T3 in free acid form (Sigma Chemicals
Co., St. Louis, MO) were dissolved in a small volume of0.05 N NaOH
and then diluted with infusion solvent. Small amounts of ['3'1]T4 or
(1251]T3 (20-30,000 cpm per pump), prepared as described further on,
were added to the T4 or T3 solutions, respectively. The radioactivity of
the pumps was determined before implanting them, and at the end of
the experiment. This permitted us to control that the delivery rate in
vivo had been the one specified by the manufacturers. Performance of
the pumps was always satisfactory.
The T4 and T3 doses indicated in Table I are referred to 100 g of
body weight (BW) at 15 d ofgestation, when the pumps were prepared
and implanted. The amount of hormone delivered daily remained
Table I. Experimental Design: Groups ofDams
and Their Treatment Schedules
MMI* Infusate
Group (14-21)t (15-2i)t
C - Solvent
MMI + Solvent
MMI+ 1.8 Mg T4 + 1.8 ug T4/100 g BW/d§ (1.3 Mg T4)
MMI+ 2.4,ug T4 + 2.4 Mg T4/I00 g BW/d (I.7 ,ug T4)
MMI+ 3.6 Mg T4 + 3.6 Ag T4/100 g BW/d (2.5 Mg T4)
MMI+ 0.5 jtg T3 + 0.5 Mg T3/100 g BW/d (0.35 Mg T3)
MMI+ 1.5 Mg T3 + 1.5 ,ug T3/I00 g BW/d (1.05 g T3)
MMI+ 4.5 ,ug T3 + 4.5 ttg T3/I00 g BW/d (3.15 Mg T3)
* 0.02% in drinking water.
Days of gestation.
§ Calculated according to the BW at 15 d of gestation, and thus de-
creasing per 100 g BW as the dams neared term. The daily dose, cal-
culated according to the BW at 21 d of gestation is shown in brackets
constant until the end of the experiment, but the dose per 100 g BW
was decreasing progressively, as the weight of the dam plus concepta
increased from 193±5 to 275±7 g between 15 and 21 d of gestation.
The doses, as referred to 100 g BW at 21 d of gestation, are shown in
brackets.
Preparations ofsamples. Maternal plasma, liver, heart, and brain
were excised. The fetuses were bled, separated from the placenta and
immediately placed on ice. The thyroid, adhering to the trachea, was
obtained under the dissecting microscope, and kept frozen. The liver,
brain, heart, and lung were dissected out, weighed and frozen rapidly
on dry ice. The interscapular brown adipose tissue (BAT) pads were
also dissected out and used for a parallel study on fetal BAT 5'-iodo-
thyronine deiodinase activity (20). The rest ofthe fetus, referred to here
as the carcass (whole embryo minus the blood, trachea, thyroid, liver,
lung, brain, heart, and BAT) was stored frozen. The fetal and maternal
sides of each placenta were separated with blunt forceps, and stored
frozen for a separate study (Calvo, R., et al., manuscript in prepara-
tion).
The thyroid glands were processed individually. Plasma from dif-
ferent fetuses were pooled, so that 300-400-Ml aliquots were obtained
for extraction and determination of T4, T3, and TSH. Carcasses were
processed individually, livers were pooled from two, brains from two to
three, lungs and hearts from four to five fetuses to obtain - 0.5 g of
tissue per pool (except for 0. 1-0. 15 g per pool ofcardiac tissue). Tissues
that were pooled were obtained from fetuses of the same litter. For
most tissues there were two individual samples or pools/dam, and thus
six pools for each of the eight experimental groups. All samples of a
given tissue were processed in the same analytical run.
Determination of T4 and T3 concentrations. All samples, including
maternal and fetal plasmas, were extracted and processed as described
in detail (8, 16). In brief, homogenization in methanol is followed by
extraction in chloroform-methanol, back-extraction into an aqueous
phase, and purification of this phase through Bio-Rad AG 1 X 2 resin
columns (Bio-Rad Laboratories, Richmond, CA). The iodothyronines
are eluted with 70% acetic acid, which is then evaporated to dryness.
RIA buffer is added, and the samples are submitted to highly sensitive
RIAs for the determination ofT4 and T3, the limits of sensitivity being
2.5 pg T4 and 1.5 pg T3/tube. Each sample is processed in duplicate or
triplicate at two or more dilutions. Results are then calculated using
individual recovery data obtained after addition of [13'I] T4 and [125I]
T3 during the initial homogenization process. The amounts of tracers
added are such that the radioactivities carried over into the RIA tubes
are too low to interfere with the determinations.
The total T4 and T3 contents of the fetal thyroids were determined
in methanol extracts of proteolytic digests of whole glands (16).
The synthesis of the high specific activity 125I- and 13'I-labeled
tracers used for individual recovery calculations and of the labeled
iodothyronines used as antigens for the T4 and T3 RIAs was carried out
as described previously (8, 16).
Other determinations. Plasma levels of thyrotrophic hormone
(TSH) were measured using immunoreactants kindly supplied by the
Rat Pituitary Agency ofthe National Institutes ofArthritis, Diabetes &
Digestive and Kidney Diseases (NIADDK) of the National Institutes
of Health (Bethesda, MD), as previously described (21). Results are
expressed in weight equivalents of the NIAMDDK-rTSH-RP-2 refer-
ence preparation.
The activity of intramitochondrial a-glycerophosphate dehydroge-
nase (a-GPD; EC 1.1.99.5) was measured in mitochondrial prepara-
tions from individual fetal livers as described by Lee and Lardy (22),
with minor modifications.
The activity of type II 5'-iodothyronine deiodinase (5' D-II) in ma-
ternal cerebral cortex (Cx) and in fetal brain was determined as de-
scribed (23, 24), using [12511] T4 (2 nM) in the presence of 20mM DTT
and I mM PTU, 100-200 gg protein/tube and a 1-h incubation at
37°C.
Statistical analysis. Mean values (±SEM) are given. Data from the
eight experimental groups were submitted to one-way analysis of vari-
ance, after testing for homogeneity of variance using Bartlett's proce-
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dure for groups of unequal size. Square root or logarithmic transfor-
mations usually ensured homogeneity of variance when this was not
found with the raw data. Significance of differences between groups
was assessed using the protected LSD (least significance difference)
test, and considered significant when P < 0.05. All these calculations
were performed as described by Snedecor and Cochran (25). Whenever
it is stated that a variable in a group is increased, or decreased, as
compared to another group, it is implied that the difference between
the mean values was statistically significant. Statistically significant
differences of data from T4- or T3-infused MMI-treated dams and
those of the C and MMI-treated animals are identified in Tables that
appear in the Appendix.
Results
Infusion doses maintaining euthyroidism
in MMI-treated dams
Maternal plasma and tissue T4 and T3 concentrations are
shown in the left-hand panels of Figs. 1 and 2, and biological
end-points of thyroid hormone action, such as circulating
TSH, cerebral cortex 5' D-II and liver a-GPD activities in the
left-hand panels of Fig. 3. In all the figures results correspond-
ing to C or MMI-treated dams are shown as shaded areas,
which enclose the mean value±SEM. The results correspond-
ing to T4 (or T3) infused MMI-treated dams are represented as
dose-response curves.
As may be seen, MMI treatment for 7 d decreased the
levels of both T4 and T3 in plasma and all maternal tissues
studied.
CHANGES IN THE CONCENTRATIONS OF T4 (FIG. 1)
In dams infused with T4. Dose-response relationships were
found between the T4 dose and T4 levels in maternal plasma
and tissues. The changes in tissues, however, were not neces-
sarily the same as in plasma. Concentrations of T4 in the heart
and liver ofMMI-treated dams infused with the 1 .8-,ag T4 dose
(for the sake of simplification, doses given henceforth refer to
the daily dose per 100 g BW per d, at 15 d of gestation, even if
this is not explicitly stated each time) were normal (that is,
comparable to those of C dams), whereas in brain they were
higher, and in plasma lower. Plasma T4 was comparable to C
values in dams infused with the 2.4-tug T4 dose, whereas T4
levels were higher than normal in all the tissues studied. Al-
though the concentrations of T4 exceeded C values in all ma-
ternal samples with the 3.6-Mg T4 dose, they did not increase
above those ofnonpregnant females of similar age (26), except
for the brain.
In dams infused with T3. Doses ranging from 0.5 to 4.5 ,ug
T3 either had no effect on T4 levels in plasma and tissues ofthe
MMI-treated dams, or actually decreased them, especially
when the highest T3 dose was used.
CHANGES IN THE CONCENTRATIONS OF T3 (FIG. 2)
In dams infused with T3. The dose-response relationships be-
tween the T3 dose and T3 levels were not the same for tissues
and plasma. T3 levels in the brain ofdams infused with 0.5 Ag
T3 did not attain C values, although T3 levels were normal in
plasma and heart, and elevated in the liver. Infusion of the
1.5-,ug T3 dose resulted in normal T3 in plasma and brain, but
liver and heart levels were higher than in C dams. The highest
T3 dose, namely 4.5 gg T3, increased T3 levels in all maternal
samples both above C values and above those of normal non-
pregnant female rats (26).
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Figure 1. The left panels show the changes in the concentrations of
T4 in maternal plasma and tissues, as a function of the dose of T4, or
T3, which was infused into the MMI-treated dams. The right panels
show the changes in the plasma and tissues of their fetuses. The cir-
cles and thick lines correspond to the T4-infused groups, the triangles
and thin lines correspond to the T3-infused groups. The SEM values
are shown as vertical lines above and below the means, unless
smaller than the size of the circles or triangles used as data points.
The darker shaded area corresponds to the T4 concentration in
plasma and tissues from C dams, or their fetuses (±SEM); the lighter
shaded area to the T4 levels in the MMI-treated dams, or their fe-
tuses. Statistically significant differences are summarized in Table AI
of the Appendix.
In dams infused with T4. T3 levels in plasma and tissues
increased with increasing doses of T4. A 1.8-ag T4 dose nor-
malized brain T3, but was inadequate to maintain normal T3
levels in plasma, heart and liver. The 2.4-Ag T4 dose resulted in
normal T3 in plasma and all tissues studied, brain included. T3
levels exceeded C values in the plasma and liver of the dams
infused with 3.6 ,gg of T4, but not in the brain and heart.
It therefore appears that no single dose of either T4 or T3
alone is able to maintain normal concentrations of both T4
and T3 in all tissues of MMI-treated dams.
Maternal Thyroid Hormone and Fetal Brain in Congenital Hypothyroidism 891
MMI+T4 T
MM¢T3
1 2 3 4
,PT
aw-m,.Jslgmmg, \ c
MMI+T3
-30 RARA.
L-sc
1
MATERNAL TISSUES
PLASMA T3
MMI+T3
MMI+T
T
1 2 3 4 l
LIVER T3
I MM+3
MMI+T4
I
0 1 2 3 4
HEARTT3
10 [
0 1 2 3 4
BRAIN T3
MMI+T3
MA
/MI+T4
c
MMI
FETAL TISSUES
PLASMA T3
0.15
0.12
MMI+T30.09
0.06a _
MMI~~M+T4
0.03rf-m - --MMl
0.00 ._ I..__ ._,.Gs_,, _
0 1 2 3 4 5
LIVER T3
0.6
0.2
C
MMI
5
0.0
1.0
!d-MI+T4
) .. ,,. . . .. . . .
0 1 2 3 4 5
HEARTT3
0.8 II
0.6 V MMI+T3 at
0.4 ;/iMM +T4
C
MMI
C
MMI
0 1 2 3 4 5
0.2
0.0
1.2,
0.9
0.6
o.3
0.0
r a
1 2 3 4 5
BRAIN T3
1..
- MMI+T4
MMI+T3
i 1 _ Ai; , ^ -..
.mr
0 1 2 3 4 5
100 mg protein, and x = ng T3/g, with r = 0.98. The a-GPD
activity usually found in non-pregnant female rats (26) was
only exceeded with the highest T3 dose.
In conclusion, a daily dose of 2.4 jig T4 was not excessive
for the MMI-treated dams. A daily dose of 1.5 ug T3 appeared
excessive for some tissues, but not for the brain, whereas 4.5 ,g
T3 was a supraphysiological dose for all maternal tissues stud-
ied here.
Effects ofmaternal treatments on thefetuses
Though data are not shown here, none ofthe treatments (MMI
for 7 d, with or without concomitant infusion of saline, T4 or
T3) affected the number of fetuses per litter. No dose-depen-
dent effects were observed on the body and organ weights of
the fetuses.
EFFECTS OF MMI ON THE FETAL THYROID
Treatment with MMI effectively blocked fetal thyroid func-
tion: total T4 contents in proteolytic digests were 35.3±1.0 and
0.22±0.02 ng/gland in fetuses from C and MMI-treated dams,
respectively, the T3 contents being 1.695±0.061 and
0.086±0.001 ng/gland. Thyroidal T4 and T3 did not increase
with the infusion of T4 or T3 into the MMI-treated dams.
Hyperemic enlarged glands were observed in all the MMI-
treated fetuses, irrespective of maternal T4 or T3 infusions.
MATERNAL TISSUES
MMI
DOSES INFUSED INTO THE MOTHERS (ftg T4 or T3 I 100 g BW / day)
Figure 2. The left panels show the changes in the concentrations of
T3 in maternal plasma and tissues, the right panels those in their cor-
responding fetuses. Data are represented as indicated in the legend to
Fig. 1. Statistically significant differences are recorded in Table AII
of the Appendix.
EFFECTS ON END-POINTS OF THYROID HORMONE ACTION
(FIG. 3)
Plasma TSH levels were increased fourfold by the 7-d treat-
ment with MMI. This increase was avoided by the concomi-
tant infusion of the dams with either T4 or T3, even at the
lowest dose. 5' D-II activity increased in the cerebral cortex of
the MMI-treated dams. Infusion of T4, but not of T3, pre-
vented this increase in dose-dependent fashion. 5' D-II was
inversely correlated to cerebral T4 (but not to T3): y
= 31.0 x-' 016, where y = fmol/h per mg protein, and x = ng
T4/g, with r = 0.98. Mean hepatic a-GPD activity was lower in
the MMI-treated as compared to the C dams, but the differ-
ence was not statistically significant. (This might be related to
the finding that liver a-GPD activity is already quite low in
normal pregnant rats at 21 d of gestation, as compared to
age-paired nonpregnant rats [26].) The a-GPD activity was
increased above MMI and C levels by the infusion of 3.6 Mg T4,
or of 1.5 or 4.5 Mg T3. Activity was linearly related to hepatic
T3 (but not to T4): y = 0.78 + 0.69x, where y = A OD/min per
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Figure 3. The left panels show the changes in plasma TSH, cerebral
5' D-II, and hepatic a-GPD in dams, the right panels those observed
in their fetuses. Data are represented as indicated in the legend to
Fig. 1. Statistically significant differences are recorded in Table AIII
of the Appendix section.
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Figure 4. Fetal tissues. The left panels show the concentrations of T4,
the right panels those of T3, in fetal lung and carcass. Data are
shown as indicated in the legend to Fig. 1. Statistically significant dif-
ferences are recorded in Table AIV of the Appendix.
EFFECTS ON FETAL EXTRATHYROIDAL T4 AND T3
CONCENTRATIONS
T4 and T3 decreased in plasma and tissues of fetuses from
MMI-treated dams, as shown in the right panels of Figs. 1 and
2, and in Fig. 4. Data for fetuses from T4- or T3-infused dams
are shown as dose-response curves.
The changes in cerebral T3 were striking: with the lowest T4
dose, T3 concentrations in the brain were almost 50% of con-
trol values, despite the fact that this dose did not increase T3 in
fetal plasma and other fetal tissues above MMI levels. Brain T3
levels were the same as those of normal fetuses with the 2.4-,ug
T4 dose, and did not exceed them in fetuses from dams receiv-
ing the highest dose. Thus, brain T3 was normal in fetuses in
which both plasma T3 and T4 were still low: T4 was - 40% of
C values, and T3 was in the MMI range.
FETAL BRAIN T4 AND T3 VERSUS TOTAL
EXTRATHYROIDAL POOLS
The total extrathyroidal T4 and T3 pools (Fig. 5, left) were
calculated by adding the amounts of each hormone contained
in plasma, fetal organs and carcass (The mean concentration
values and the mean organ weights were used to calculate the
T4 [or T3] contents in each tissue. The mean total blood vol-
ume was calculated as 16.8% of body weight, based on data
obtained in rat fetuses near term [27]. Data for BAT were from
Obregon et al. [20].): The values obtained for normal fetuses
were taken as 100%. The cerebral T4 and T3 contents are repre-
sented in similar fashion in the right-hand panel of Fig. 5.
Comparison of both panels stresses the finding that brain T3
was normal in fetuses from MMI-treated dams infused with
doses of T4 which were insufficient to avoid T4 and T3 defi-
ciency of the fetus as a whole. T3 deficiency of the fetus could
be prevented by the infusion of a supraphysiological dose of
T3, but this had no mitigating effect on fetal brain T3 defi-
ciency.
Changes in the concentrations of T4 (Figs. I and 4)
Infetusesfrom dams infused with T4. The infusion ofT4 miti-
gated the effect ofMMI on T4 levels in fetal plasma and tissues,
even at the lowest (1.8 Atg) dose. Normal (C) values, however,
were not reached even with the highest dose, namely 3.6 jig T4:
the T4 concentrations closest to C values were found in plasma
and brain, the lowest in lung.
In fetuses from dams infused with T3. The T4 concentra-
tions in plasma, brain, liver, heart, carcass, and lung of fetuses
from MMI-treated dams were either unchanged by the infu-
sion of the dams with T3, or actually decreased further, espe-
cially with the 4.5-,ug T3 dose.
EFFECTS ON FETAL END-POINTS OF THYROID HORMONE
ACTION (FIG. 3)
Both fetal plasma TSH and fetal brain 5' D-II increased mark-
edly with MMI treatment. Both increases were avoided in a
dose-dependent fashion by the concomitant infusion of T4
into the mothers, but not by the infusion of T3. Both end-
points were inversely related to the respective T4 concentra-
tions. The relationship between cerebral 5' D-II and T4 was y
= 25.9 x' 7 (with y = fmol/h per mg protein, and x = ng T4/g
brain), r = 0.97, and was quite similar to the one found for the
cerebral cortex of their mothers.
WHOLE FETUS FETAL BRAIN
Changes in the concentrations of T3 (Figs. 2 and 4)
In fetuses from dams infused with T3. Dose-response relation-
ships were observed between the T3 level in a fetal tissue and
the dose of T3 infused into the mother, the degree of change
being tissue specific. Normal T3 levels were reached with the
1.5-,gg T3 dose in plasma and liver, but not in heart, lung, or
carcass. Normal fetal T3 levels were only reached in carcass
and lung with the highest dose, namely 4.5 ,tg T3, although T3
levels in plasma, liver, and heart clearly exceeded C values.
Changes in fetal brain T3 are in marked contrast with those
in fetal plasma and other tissues: T3 concentrations were not
increased above the MMI levels even with the infusion of 4.5
,ug T3, which raised fetal plasma T3 above C levels.
In fetuses from dams infused with T4. The infusion of the
two lower doses of T4 hardly affected T3 levels in most fetal
tissues, brain excepted. With the 3.6-jsg T4 dose normal fetal
T3 levels were reached in plasma and heart, but not in other
tissues.
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Figure 5. The left panel shows the total extrathyroidal pools of T4
(light-hatched bars) and of T3 (dark-hatched bars) in fetuses from C
and MMI-treated dams, and from T4 or-T3-infused MMI-treated
dams. The extrathyroidal pools corresponding to C fetuses (1 1. 19 ng
T4 and 2.42 ng T3) are taken as the 100% values. The right panel
shows the amounts of T4 and T3 in the fetal brain. The values corre-
sponding to C fetuses (0.221 ng T4 and 0.208 ng T3) are taken as the
100% values.
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Fetal plasma TSH and T4 were inversely related, y
= 8.99 . 10-01'96X (where y = ng TSH/ml, and x = ng T4/ml), r
= 0.98. In contrast with findings in the mothers, fetal plasma
TSH and T3 levels were not inversely related. Plasma TSH in
fetuses from T3-infused dams was as high as in fetuses from
dams on MMI alone, even with the highest T3 dose, which
increased fetal plasma T3 above C levels.
Changes in a-GPD activities in the fetal liver were not as
clearly thyroid hormone-dependent as in the maternal liver,
although the infusion of T3 into the MMI-treated dams ap-
peared to have a dose-related effect.
Discussion
Maintainance of maternal euthyroidism: T4 versus T3. Infu-
sion ofeither T4 or T3 alone does not normalize both T4 and T3
in plasma and all tissues. The 2.4-,ug T4 dose increased T3 in
maternal plasma and tissues to normal levels and also reversed
several biological end-points of thyroid hormone action to
normal values, although T4 concentrations were higher than in
normal pregnant dams. Gray and Galton (28) found that daily
subcutaneous injections of 2 ,gg T4/100 g BW maintained thy-
roidectomized pregnant rats euthyroid. They increased the
dose with increasing BW, so that near term it was actually very
similar to the present 2.4 ,g T4 infusion dose, which was 1.7 Ag
T4/100 g BW per d by 21 d of gestation. The present MMI-
treated dams on this dose were considered equivalent to euthy-
roid C dams. So were the MMI-treated dams receiving the 0.5-
to 1.5-jig T3 doses, although it must be kept in mind that they
differed from normal euthyroid dams in an important respect,
namely, that they have very low T4 pools and are thus deprived
of substrate for regulatory mechanisms involving local genera-
tion of T3 from T4 (29).
Transfer of T4 and T3 from the mother to the conceptus.
Comparison of changes in T4 and T3 levels in maternal versus
fetal samples (fetal brain T3 excluded) confirms that both io-
dothyronines cross the rat placenta near term (16, 17). The
fetal T4 and T3 levels are related to the dose of the parent
iodothyronine infused into the mothers, but the slopes of the
dose-response curves are lower for fetal, as compared to ma-
ternal, plasma and tissues. Transfer is, therefore, not free, but
limited. It is quite likely that the placenta plays an important
role in this, as previously proposed by others (2) and reported
elsewhere (Calvo, R., et al., in preparation).
Present results contradict the notion that the placenta
avoids transfer ofany T4 or T3 from the mother to the fetus (2,
15). We have indeed recently found that at 21 d of gestation
the net maternal contribution represents 17.5±0.9% of the
total fetal extrathyroidal T4 pool (30) (Normal dams were in-
fused with high specific activity [1251] T4, plus KI to block 125I
recycling, from 11 to 21 d of gestation, at which time isotopic
equilibrium was reached and the specific activity of the [12511]
T4 was determined in maternal and fetal tissues. Comparison
of these values allows calculation of the net maternal contri-
bution to fetal extrathyroidal T4 [30].) Moreover, preliminary
data indicate that transfer of T4 is not increased, in absolute
amounts, by MMI-induced fetal thyroid failure (30).
Infusion ofT4 versus T3 into the mother; differential effects
onfetal thyroid hormone economy. Present results, as summa-
rized in Fig. 5, show that infusion of T4 into the mothers
mitigates both the T4 and T3 deficiency ofthe fetus as a whole,
and is especially beneficial for the fetal brain. In contrast,
maintainance of maternal euthyroidism with T3 deprives the
fetus of regulatory mechanisms that require T4 for the intra-
cellular supply of T3 (29), as already indicated for their
mothers.
The consequences of an inadequate supply of T4 are more
dramatic for the fetal than for the adult brain. Administration
of a dose of T3 which was clearly supraphysiological for the
mother did not increase fetal brain T3 above MMI levels, de-
spite restoration of the total extrathyroidal T3 pool to normal
values.
Thus, the fetal brain appears to depend on local conversion
of T4 to T3 for its T3 supply to a much greater extent than in
adult rats, as previously discussed (17, 23). This had been doc-
umented for neonatal rats 2 wk after birth by Silva and
Matthews (31). The fetal brain is exclusively dependent on
local generation of T3 from T4, although in the mothers a
certain proportion of intracerebral T3 is derived from plasma
T3. For non-pregnant adult rats almost half the T3 bound to
nuclei would be derived from plasma T3 according to Crantz et
al. (32), about 33% for cortex and 50% for cerebellum accord-
ing to van Doorn et al. (33). Dickson et al. (34) have shown
that the choroid plexus of adult rats accumulates T4, but not
T3, in vitro. This structure appears to be important in the
transfer of the iodothyronines into the brain. Present results
suggest that the difference between the uptake of T4 and T3
might be even greater during fetal development, and/or that
alternative pathways for the entry of the iodothyronines into
the brain, which would account for uptake of T3 from plasma
in adult rats, have not yet developed.
T4 and T3 concentrations were not measured in the fetal
pituitaries because of technical difficulties. The dose-response
curves obtained for fetal plasma TSH, however, suggest that
the changes in T4 and T3 levels in the pituitary would resemble
those observed in the fetal brain. It is possible that the contri-
bution of plasma T3 to intrapituitary T3 content is lower dur-
ing fetal life than it is in adults and depends, as is the case for
the brain, mostly on local conversion of T4 to T3 for its intra-
cellular supply of T3. The rat pituitary is apparently not sensi-
tive to T3 until 5 d postnatally (35), although Knobil and
Josimovich (36) found some limited effects of very high doses
ofT3 on the fetal pituitary, as measured by an antigoiter assay.
The lack of participation of plasma-derived T3 in the cere-
bral (and possibly, hypophyseal) supply ofT3 during fetal life is
not, however, a general characteristic of tissues with high 5'
D-II activities. T3 concentrations in fetal BAT (20) not only
increased with the infusion of 2.4 and 3.6 ,ug T4 into the dams,
but also when the 4.5-,ug T3 dose was infused.
Maternal thyroxinemia and the preferential protection of
the fetal brain from T3 deficiency. We wish to stress that a
normal maternal thyroxinemia (dams on the 2.4-,gg T4 dose)
results in the preferential protection of the brain in fetuses
which would be detected as congenitally hypothyroid on the
basis of their plasma T4 (only 40% of normal), and their ele-
vated plasma TSH. "Clinical" signs of congenital hypothy-
roidism might be detected in such fetuses near term (or in the
newborns), but this would not necessarily mean that the brain
had also been T3 deficient in utero, provided maternal thyrox-
inemia was normal. A relatively minor degree of maternal
hypothyroxinemia (dams on the 1.8-,ug T4 dose) would no
longer be adequate for total protection: T3 was only 50% of
normal. In contrast, a slightly increased maternal thyroxin-
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emia (dams on the 3.6-Atg T4 dose), did not result in excessive
fetal brain T3. Extrapolation of the dose-response curves for
fetal brain T4 concentrations (Fig. 1) and 5' D-II activity (Fig.
3) suggests that normal brain T4 levels and 5' D-II activities
might not be reached until the dose infused into the dams
increased to 5-6 tug T4/100 g BW/d considering that brain 5'
D-II is regulated by the concentration of T4, not by T3 levels in
the physiological range (37). It seems unlikely that fetal brain
T3 levels would become excessive until the maternal supply of
T4 exceeded these doses, which are approximately double the
dose ensuring maternal euthyroidism. This point, however,
remains to be investigated.
Mechanisms involved in the preferential protection of the
fetal brainfrom T3 deficiency. The mechanisms which lead to a
preferential protection during this important period of neuro-
genesis are not yet well defined. The ability of fetal brain 5' o-II
to increase four- to fivefold in response to hypothyroidism (22)
obviously plays an important role. It is also possible that a
decrease in inner-ring iodothyronine deiodinase activity con-
tributes to the increase in cerebral T3: activity ofthis enzyme is
high in fetal brain and, contrary to 5' D-II, decreases with
hypothyroidism (38). Cerebral uptake of T4 might also be in-
creased, as suggested indirectly by the concentrations of the
iodothyronines in plasma and tissues. Although plasma T4 and
T3 in C fetuses are only 20.7% and 12.5%, respectively, of the
maternal levels, and fetal liver T4 and T3 are 19.8% and 13.2%
of those in maternal liver, fetal brain T4 and T3 are 140% and
77% of maternal cerebral levels. The brain to plasma T4 ratio
was almost seven times higher in the brain ofC fetuses (0.364)
than in the maternal brain (0.054), whereas liver to plasma T4
ratios were very similar for C dams (1.16) and their fetuses
( 1.1 1). Previous studies carried out in 2-wk-old rat pups (29)
showed that the neonatal brain responds to hypothyroidism
with an increase in cerebral conversion of T4 to T3, in T3
residence time, and in T3 uptake.
Conclusions regarding the main aims of this study. The
findings presented here show that a normal maternal supply of
T4 is essential for the preferential protection of the fetal brain
from T3 deficiency. A 50% increase in the maternal supply of
T4 above the "physiological" dose does not result in excessive
brain T3. The fetal brain is entirely dependent on T4, and not
on plasma T3, for its intracellular supply of T3 (23). Thus,
unless maternal hypothyroxinemia is corrected, maintainance
of maternal euthyroidism with T3 is of no benefit for the fetal
brain, although T3 deficiency is mitigated in other tissues.
Even doses of T3 high enough to be in the toxic range for the
mothers do not increase fetal brain T3 above hypothyroid
levels.
Clinical implications. The recent report by Vulsma et al.
(19) regarding maternal transfer of thyroid hormones in man
lends greater relevance to present findings in the rat as a model
for human congenital hypothyroidism. Transfer ofT4 from the
mother to the hypothyroid fetus at term is enough to ensure T4
levels at birth that are 25-50% of normal. Despite older evi-
dence showing maternal transfer of the iodothyronines
(39-41), the more recent consensus was that it would be negli-
gible in quantitative terms (1, 2, 42, 43). This notion was partly
due to the lack ofeffect ofincreasing doses ofT3 on cord-blood
TSH (44, 45). Present results in rats suggest that T3 was actu-
ally transferred to the fetus, but that at this stage of develop-
ment the pituitary is not yet as sensitive to plasma T3 as in
adults.
Maternal transfer of thyroid hormones is not sufficient to
compensate completely for the lack of fetal thyroid function:
babies with congenital thyroid failure are often born with signs
of hypothyroidism, such as the absence of ossification centers
that are present at birth in normal babies (4, 46-48). More-
over, most of their central nervous system (CNS) damage may
be prevented by prompt postnatal treatment (49-51). From
these observations it has been concluded (4, 15) that transfer is
physiologically irrelevant and the human brain does not re-
quire thyroid hormone for normal development until after
birth. The latter conclusion, however, does not take into con-
sideration that not all of the CNS damage is prevented by
immediate and proper postnatal treatment (49-52). The hy-
pothesis also contrasts with evidence in species, such as the rat,
where thyroidectomy at a stage of brain development grossly
equivalent to that of a human fetus at mid-gestation results in
profound effects on many phases of brain maturation that
occur in utero in man (for reviews, and references of previous
reviews, see 52-54). Moreover, Stein et al. (55) have recently
found decreased abundance of EGF and M#5 tubulin isomer
mRNAs in the cerebral cortex of congenitally hypothyroid
mice on the day of birth, clearly showing thyroid hormone
dependence of the brain during fetal life.
Present results afford an alternative interpretation, namely
that thyroid hormones are important for phases of human
brain development occurring in utero. Their supply in early
pregnancy is of maternal origin, and later of combined fetal
and maternal origins. Maternal transfer of T4 could still pro-
vide the fetal brain with sufficient T3 to avoid major irrevers-
ible CNS damage if the fetal thyroid is impaired. Cerebral T3
deficiency would supervene after birth, and would be pre-
vented by prompt T4 therapy. The fetal brain might be pro-
tected by maternal T4 even if transfer is not sufficient for other
tissues. Signs of intrauterine hypothyroidism (i.e., delayed
skeletal maturation) do not necessarily mean the brain was T3
deficient before birth.
The degree of protection might, however, be variable and
depend on maternal T4 levels, and/or the permeability of the
placenta. The hypothyroid fetus would be more severely af-
fected, and the protection of the fetal brain less complete,
when the degree oftransfer is low. Several studies (49-52) have
indeed shown that the babies with the poorest prognosis as
regards their CNS development, despite prompt postnatal
treatment, are those with the most severe retardation of bone
maturation and with the lowest T4 at screening.
The most severe CNS damage, possibly irreversible by the
time of birth, would result from combined fetal and maternal
hypothyroxinemia. In areas of marked iodine deficiency,
where neurological cretins are born, pregnant women have
very low levels of circulating total and free T4 (13). The fetus is
deprived of T4 throughout pregnancy, initially because of ma-
ternal hypothyroxinemia, and later in gestation because ma-
ternal hypothyroxinemia continues and the fetal thyroid can-
not produce enough T4 due to the scarce supply of iodine ( 12,
13). Maternal levels of total and free T3 are normal and may
prevent the manifestation of clinical hypothyroidism in such
women and in the neurological cretins born from them (56).
But despite normal T3 levels, the CNS was deprived of T4 and,
consequently, of locally generated T3, during very important
phases of development, which in man occur in utero. A single
case reported in the United States with the full clinical picture
of neurological cretinism, without iodine deficiency, was the
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congenitally hypothyroid son of a hypothyroid mother (57).
Carr et al. (58) described a previous case ofcombined fetal and
maternal hypothyroidism, but treated the mother with high
doses of desiccated thyroid, and treated the child from birth,
apparently with success.
It is at present not possible to assess poor permeability of
the placenta per se. But maternal hypothyroxinemia (low
levels of "free" T4) could be avoided by adequate controls
during pregnancy. Treatment with T3 should be avoided, as it
might decrease maternal T4 pools. Maintainance ofT4 levels in
the upper range ofnormality (or even somewhat above it when
fetal hypothyroidism is suspected) should be aimed at to pro-
tect the brain up to birth. Present comments might also be
pertinent for thyrotoxic women on antithyroid drug treatment
during pregnancy. In this condition the therapeutic goal is to
achieve a euthyroid or slightly hyperthyroid mother and to
prevent fetal hypothyroidism or hyperthyroidism (59). There
is a general consensus that maternal hypothyroidism is to be
avoided (43, 59-62), and present results strongly advocate
maintainance of normal (or slightly elevated) maternal T4.
Whether this is to be ensured by treating with minimal doses of
antithyroid compounds, thyroidectomy and T4 replacement,
or the regimen combining low doses of antithyroid drugs and
T4 supplementation has been, and still is, matter for debate
(43, 59-62). The latter treatment, used by Selenkow et al. (60)
with good results, apparently did not receive greater accep-
tance, because ofthe widespread beliefthat T4 would not cross
the placenta or benefit the fetus. We do not know whether
treatment is also indicated for those pregnant women who
have low levels of free T4 due to causes not directly related to
primary hypothyroidism (i.e., severe illness). Further studies
are needed to ensure whether in such cases the mechanisms
involved in the preferential protection of the fetal brain are
operative, or affected by the condition of the mother.
In a recent editorial commenting the results of Vulsma et
al. (19), Larsen (63) concludes: "It follows that if we ensure a
euthyroid state during pregnancy and ifparents and physicians
try rigorously to provide adequate replacement therapy there-
after, it is not unrealistic to expect that even athyreotic infants
whose condition is discovered by thyroid screening programs
can reach their full intellectual potential." We fully agree with
the general concepts underlying this conclusion, but also be-
lieve that present results strongly suggest that it is essential to
define more precisely the maternal "euthyroid state during
pregnancy." The degree of protection of the fetal brain is re-
lated to maternal thyroxinemia, and not to maternal "euthy-
roidism." Therefore, it is normal availability of maternal T4
which has to be ensured, whether or not clinical euthyroidism
is maintained by normal levels of T13.
Appendix
Table AL
Maternal tissues Fetal tissues
Plasma Liver Heart Brain Plasma Liver Heart Brain
T4 T4 T4 T4 T4 T4 T4 T4
(In x) (In x) (In x) (In x) (xO5) (In x) (x05) (x05)
Groups: C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI
1.8 Ag T4 NS * NS $ NS * * 4 4 4 4 § $ NS * NS
2.4,gT4 NS * § $ * 4 $ $ $ 4 $ $ $ § * *
3.6 j&g T4 * * $ $ § $ * * * * * * § § * *
0.5ugg T3 NS * NS * NS $ NS $ NS $ NS $ NS * NS
1.5 gT3 * NS * NS $ NS § NS $ * * NS * NS * NS
4.5 jgT3 * * $ NS § NS * NS $ § 4 * * * * NS
Corresponds to Fig. 1. It identifies the statistically significant differences in the concentration of T4 in plasma and tissues of MMI-treated dams
(or of their fetuses) infused with T4 or T3, as compared both to the C and the MMI-treated groups. The transformation of the data required for
homogeneity of variances is given in brackets: (-) indicates that the variances were homogeneous using the raw data. All T4 values for the
MMI-treated dams or their fetuses were significantly decreased versus C. NS, Not significantly different. * P < 0.05. §P < 0.01. tP < 0.001.
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Table AIl.
Maternal tissues Fetal tissues
Plasma Liver Heart Brain Plasma Liver Heart Brain
T3 T3 T3 T3 T3 T3 T3 T3
(-) (In x) (ln x) (xo5) (-) (In x) (-) (ln x)
Groups: C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI
1.8 gT4 * NS t NS § NS NS * t NS t NS t NS t §
2.4 AgT4 NS * NS t NS § NS § t NS * NS t NS NS t
3.6 qgT4 § $ § X NS t NS t NS $ § § NS t NS t
0.5 ug T3 NS NS * t NS * * NS t NS NS t t NS t §
1.5uAg T3 NS NS § t * NS t NS * NS t t NS t *
4.5 Ag T3 * * * * * t t t * * NS t t NS
Corresponds to Fig. 2. It identifies the statistically significant differences between the concentration of T3 in plasma and tissues of MMI-treated
dams (or of their fetuses) infused with T4 or T3, as compared to those ofC and of MMI-treated groups. All T3 values for the MMI-treated
dams (or their fetuses) were significantly decreased versus C. * P < 0.05. § P < 0.01. t P < 0.001.
Table AIII.
Maternal tissues Fetal tissues
Plasma Brain Liver Plasma Brain Liver
TSH 5' D-II a-GPD TSH 5' D-II a-GPD
(-) (In x) (-) (x05) (in x) (-)
Groups: C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI C vs. MMI
1.8 gT4 NS NS NS NS NS NS *
2.4 gT4 NS $ § NS NS $ NS NS
3.6 qgT4 NS t * § * * NS NS
0.5 AgT3 NS $ t NS NS NS NS NS *
1.5 jglg3 NS $ § NS * § $ * NS § NS
4.5ttg T3 NS NS NS NS NS §
Corresponds to Fig. 3. It identifies statistically significant changes in plasma TSH, cerebral 5' D-II and hepatic a-GPD activities of MMI-treated
dams (or of their fetuses) infused with T4 or T3, as compared to data from C and from MMI-treated groups. Values for MMI-treated dams (or
their fetuses) were different from those of the C animals, except for maternal a-GPD activity. * P < 0.05. § P < 0.01. $ P < 0.001.
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2.4 AgT4 $ $ * $ $ $ *
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